These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 21340770)

  • 1. In vitro invasion assays.
    Chambers SK
    Methods Mol Med; 2001; 39():179-85. PubMed ID: 21340770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B.
    Kobayashi H; Ohi H; Sugimura M; Shinohara H; Fujii T; Terao T
    Cancer Res; 1992 Jul; 52(13):3610-4. PubMed ID: 1617632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of proteases as anticancer drugs.
    Jedinak A; Maliar T
    Neoplasma; 2005; 52(3):185-92. PubMed ID: 15875078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
    Masson V
    Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
    Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
    Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse trophoblastic cell lines: II--Relationship between invasive potential and proteases.
    Sharma RK
    In Vivo; 1998; 12(2):209-17. PubMed ID: 9627804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.
    Chambers SK; Wang Y; Gertz RE; Kacinski BM
    Cancer Res; 1995 Apr; 55(7):1578-85. PubMed ID: 7882368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
    Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
    Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein C and its inhibitor in malignancy.
    Suzuki K; Hayashi T
    Semin Thromb Hemost; 2007 Oct; 33(7):667-72. PubMed ID: 18000793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation.
    Emenaker NJ; Basson MD
    J Surg Res; 1998 Apr; 76(1):41-6. PubMed ID: 9695737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
    Schmitt M; Jänicke F; Graeff H
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
    Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
    Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
    Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
    Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-derived neurotrophic factor inducing angiogenesis through modulation of matrix-degrading proteases.
    Sun CY; Hu Y; Wang HF; He WJ; Wang YD; Wu T
    Chin Med J (Engl); 2006 Apr; 119(7):589-95. PubMed ID: 16620701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
    Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ
    Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems.
    Krol J; Sato S; Rettenberger P; Assfalg-Machleidt I; Schmitt M; Magdolen V; Magdolen U
    Biol Chem; 2003 Jul; 384(7):1085-96. PubMed ID: 12956425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases.
    Kim MH
    J Cell Biochem; 2003 Jun; 89(3):529-38. PubMed ID: 12761886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and activation of proteases in co-cultures.
    Paduch R; Kandefer-Szerszeń M
    Exp Toxicol Pathol; 2011 Jan; 63(1-2):79-87. PubMed ID: 19836935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.